The authors reweighted the LEADER placebo-controlled trial of liraglutide onto Veterans Affairs cohorts with type 2 diabetes, balancing baseline characteristics between trial and veterans. The three-year reduction in major cardiovascular events was 4.6% in the reweighted veterans against 1.6% in the trial itself. All-cause mortality moved the same way, 2.9% against 0.9%, although both differences remain within the uncertainty around the trial's estimates.
Why it is interesting: Shows how far a GLP-1 trial's effect moves when carried to a higher-risk population.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.